Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Consensus Rating of “Hold” by Brokerages

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) have earned an average rating of “Hold” from the six analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $3.2250.

Several analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research note on Thursday, January 22nd. Wall Street Zen downgraded shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th.

Lexicon Pharmaceuticals Stock Performance

Lexicon Pharmaceuticals stock opened at $1.50 on Friday. The stock has a 50-day moving average price of $1.32 and a 200 day moving average price of $1.31. The company has a market capitalization of $545.21 million, a price-to-earnings ratio of -7.89 and a beta of 0.98. Lexicon Pharmaceuticals has a 52 week low of $0.28 and a 52 week high of $1.83. The company has a quick ratio of 5.63, a current ratio of 5.64 and a debt-to-equity ratio of 0.47.

Insider Transactions at Lexicon Pharmaceuticals

In related news, Director Invus Global Management, Llc acquired 1,538,462 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was acquired at an average price of $1.30 per share, with a total value of $2,000,000.60. Following the acquisition, the director directly owned 1,538,462 shares in the company, valued at $2,000,000.60. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Raymond Debbane bought 100,000 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The shares were bought at an average cost of $1.47 per share, for a total transaction of $147,000.00. Following the completion of the acquisition, the director owned 1,904,186 shares of the company’s stock, valued at $2,799,153.42. This trade represents a 5.54% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 1,788,462 shares of company stock valued at $2,367,001 in the last quarter. Company insiders own 13.90% of the company’s stock.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

Large investors have recently made changes to their positions in the company. R Squared Ltd boosted its holdings in Lexicon Pharmaceuticals by 45.3% during the fourth quarter. R Squared Ltd now owns 46,579 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 14,530 shares in the last quarter. Savant Capital LLC raised its position in shares of Lexicon Pharmaceuticals by 33.2% in the second quarter. Savant Capital LLC now owns 69,578 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 17,348 shares during the period. Bank of America Corp DE boosted its stake in shares of Lexicon Pharmaceuticals by 80.1% during the 3rd quarter. Bank of America Corp DE now owns 57,804 shares of the biopharmaceutical company’s stock worth $78,000 after acquiring an additional 25,707 shares in the last quarter. Vermillion & White Wealth Management Group LLC grew its position in shares of Lexicon Pharmaceuticals by 400.0% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 32,500 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 26,000 shares during the period. Finally, Security National Bank of Sioux City Iowa IA acquired a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter valued at about $31,000. 74.70% of the stock is currently owned by institutional investors and hedge funds.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.